BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.
HEALTH AND HUMAN SERVICES, DEPARTMENT OF is actively seeking qualified contractors for research and development in biotechnology (except nanobiotechnology) with a set-aside for No Set Aside businesses in WASHINGTON, DC. This set-aside designation means eligible businesses face reduced competition from larger firms.
Looking for more opportunities?
Browse our full directory of government contracts